Gemcitabine-mediated radiosensitization of human soft tissue sarcoma

Area of Science:

• Oncology
• Radiation Oncology
• Medical Oncology

Background:

• Soft tissue sarcoma (STS) presents challenges for local and systemic control, especially in retroperitoneal, deep truncal, or advanced extremity locations.
• 2',2'-Difluoro-2'-deoxycytidine (gemcitabine) is a known radiosensitizer but its efficacy in human STS has not been previously investigated.

Purpose of the Study:

• To evaluate the radiosensitizing potential of gemcitabine in preclinical models of human STS.
• To determine if gemcitabine can enhance the efficacy of radiotherapy in STS.

Main Methods:

• In vitro radiosensitization was assessed using clonogenic survival assays on three human STS cell lines (leiomyosarcoma, liposarcoma, fibrosarcoma).
• In vivo studies utilized SK-LMS-1 nude mice xenografts treated with concurrent gemcitabine and fractionated radiotherapy (30 Gy total).

Main Results:

• Gemcitabine demonstrated significant in vitro radiosensitization across all tested STS cell lines, with maximal effect linked to early S-phase cell cycle accumulation.
• Combined gemcitabine and radiotherapy significantly delayed tumor growth in SK-LMS-1 xenografts compared to monotherapy.
• Toxicity was manageable and acceptable in the combination treatment arm.

Conclusions:

• Gemcitabine acts as a potent radiosensitizer in preclinical human STS models.
• Clinical trials investigating the combination of gemcitabine and radiotherapy for STS are recommended.